Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide

Journal of Pineal Research

Volumn 51, Issue 3, 2011, Pages 324-330

  Dayoub, José C ^a,b   Ortiz, Francisco ^a,b   Lõpez, Luis C ^a,b   Venegas, Carmen ^a,b   Del Pino Zumaquero, Alberto ^a,b   Roda, Olga ^b   Sánchez Montesinos, Indalecio ^b   Acuña Castroviejo, Darío ^a,b   Escames, Germaine ^a,b  

^a Centro de Investigación   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

atorvastatin; endothelial nitric oxide synthase; human umbilical vein endothelial cells; melatonin; oxidative stress

Indexed keywords

ATORVASTATIN; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FREE RADICAL; INTERLEUKIN 6; MELATONIN; MESSENGER RNA;

ARTICLE; CELL CULTURE; CELL DAMAGE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

BASE SEQUENCE; BLOTTING, WESTERN; CELLS, CULTURED; DNA PRIMERS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FREE RADICALS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; MELATONIN; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PYRROLES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80053183010     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00892.x     Document Type: Article

References (57)

1. Laufs U, Liao JK,. Rapid effects of statins: from prophylaxis to therapy for ischemic stroke. Arterioscler Thromb Vasc Biol 2003; 23: 156-157. (Pubitemid 36231921)
2. Larosa JC, Hunninghake D, Bush D, et al., The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81: 1721-1733. (Pubitemid 20158316)
3. Papaharalambus CA, Griendling KK,. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007; 17: 48-54. (Pubitemid 46205327)
4. Surekha RH, Srikanth BB, Jharna P, et al., Oxidative stress and total antioxidant status in myocardial infarction. Singapore Med J 2007; 48: 137-142. (Pubitemid 351229415)
5. Berry C, Brosnan MJ, Fennell J, et al., Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001; 10: 247-255. (Pubitemid 32221768)
6. Tengattini S, Reiter RJ, Tan DX, et al., Cardiovascular diseases: protective effects of melatonin. J Pineal Res 2008; 44: 16-25. (Pubitemid 350231106)
7. Choi YJ, Lee MK, Lee YJ, et al., Inhibition of hydrogen peroxide-induced endothelial apoptosis by 2′,4′,7-trihydroxyflavanone, a flavonoid form. J Med Food 2004; 7: 408-416.
8. Davignon J, Jacob RF, Mason RP,. The antioxidant effects of statins. Coron Artery Dis 2004; 15: 251-258. (Pubitemid 39061608)
9. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
10. Reiter RJ, Tan DX, Mayo JC, et al., Melatonin, longevity and health in the aged: an assessment. Free Radic Res 2002; 36: 1323-1329. (Pubitemid 35469519)
11. Guven A, Yavuz O, Cam M, et al., Melatonin protects against epirubicin-induced cardiotoxicity. Acta Histochem 2007; 109: 52-60. (Pubitemid 46176047)
12. Tan DX, Chen LD, Poeggeler B, et al., Melatonin: a potent hydroxyradical scavenger. Endocr J 1993; 1: 40-57.
13. Mukherjee D, Roy SG, Bandyopadhyay A, et al., Melatonin protects against isoproterenol-induced myocardial injury in the rat: antioxidative mechanisms. J Pineal Res 2010; 48: 251-262.
14. Lee S, Jadhav V, Ayer RE, et al., Dual effects of melatonin on oxidative stress after surgical brain injury in rats. J Pineal Res 2009; 46: 43-48.
15. Ressmeyer AR, Mayo JC, Zelosko V, et al., Antioxidant properties of the melatonin metabolite N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8: 205-213. (Pubitemid 37236233)
16. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
17. Hardeland R,. Antioxidant protein of melatonin. Endocrine 2009; 27: 119-130.
18. Mayo JC, Sainz RM, Tan DX, et al., Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005; 165: 139-149. (Pubitemid 40984631)
19. Escames G, Leõn J, Macías M, et al., Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003; 17: 932-934.
20. Chucharoen P, Chetsawang B, Putthaprasart C, et al., The presence of melatonin receptors and inhibitory effect of melatonin on hydrogen peroxide-induced endothelial nitric oxide synthase expression in bovine cerebral blood vessels. J Pineal Res 2007; 43: 35-41. (Pubitemid 47035219)
21. Xia CM, Shao CH, Xin L, et al., Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol 2008; 35: 1258-1264.
22. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. Wang H, Joseph JA,. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 1999; 27: 612-616. (Pubitemid 29408648)
24. Esterbauer H, Cheeseman KH,. Determination of aldehidic lipid peroxidation products: malonaldehide and 4-hydroxynonenal. Methods Enzymol 1990; 186: 407-421. (Pubitemid 20279982)
25. Albrecht ED, Aberdeen GW, Niklaus AL, et al., Acute temporal regulation of vascular endothelial growth/permeability factor expression and endothelial morphology in the baboon endometrium by ovarian steroids. J Clin Endocrinol Metab 2003; 88: 2844-2852. (Pubitemid 36724466)
26. Jones SP, Gibson MF, Rimmer DM III, et al., Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40: 1172-1178.
27. Tamura EK, Silva CL, Markus RP,. Melatonin inhibits endothelial nitric oxide production in vitro. J Pineal Res 2006; 41: 267-274. (Pubitemid 44337723)
28. Pechanova O, Zicha J, Paulis L, et al., The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 2007; 561: 129-136. (Pubitemid 46435853)
29. Cagnacci A, Arangino S, Angiolucci M, et al., Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin Endocrinol (Oxf) 2001; 54: 261-266. (Pubitemid 32193529)
30. Knepler JL Jr, Taher LN, Gupta MP, et al., Peroxynitrite causes endothelial cell monolayer barrier dysfunction. Am J Physiol Cell Physiol 2001; 281: C1064-C1075.
31. Escames G, Lõpez LC, Tapias V, et al., Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006; 40: 71-78.
32. Chen XN, Xu J, Feng Z, et al., Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation. Acta Pharmacol Sin 2010; 31: 813-820.
33. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
34. Reiter RJ, Tan DX, Paredes SD, et al., Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42: 276-285.
35. Liao JK,. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86: 5-18. (Pubitemid 35247880)
36. Wagner AH, Kohler T, Ruckschloss U, et al., Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-69. (Pubitemid 30048347)
37. Christ M, Bauersachs J, Liebetrau C, et al., Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. Diabetes 2002; 51: 2648-2652. (Pubitemid 34827419)
38. Jou MJ, Peng TI, Hsu LF, et al., Visualization of melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48: 20-38.
39. Leon J, Acuna-Castroviejo D, Sainz RM, et al., Melatonin and mitochondrial function. Life Sci 2004; 75: 765-790. (Pubitemid 38737416)
40. Leon J, Acuna-Castroviejo D, Escames G, et al., Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38: 1-9. (Pubitemid 40139304)
41. Acuna-Castroviejo D, Martin M, Macias M, et al., Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001; 30: 65-74. (Pubitemid 32176208)
42. Acuna-Castroviejo D, Escames G, Leon J, et al., Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527: 549-557. (Pubitemid 38197684)
43. Fabrizio RL, Bonomini F, Rezzani R, et al., Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice. Acta Histochem 2007; 109: 45-51. (Pubitemid 46188338)
44. Yamamoto K, Ikeda U, Shimada K,. Role of mechanical stress in monocytes/macrophages: implications for atherosclerosis. Curr Vasc Pharmacol 2003; 1: 315-319.
45. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, et al., Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002; 160: 49-58. (Pubitemid 34082716)
46. Zhang L, Zhang S, Jiang H, et al., Effects of statin therapy on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. Arch Med Res 2010; 41: 464-471.
47. Crespo E, Macías M, Pozo D, et al., Melatonin inhibits expression of the inducible NO synthase II in liver and lung and prevents endotoxemia in lipopolysaccharide-induced multiple organ dysfunction syndrome in rats. FASEB J 1999; 13: 1537-1546. (Pubitemid 29411787)
48. Hardeland R, Pandi-Perumal SR, Cardinali DP,. Melatonin. Int J Biochem Cell Biol 2006; 38: 313-316. (Pubitemid 41821880)
49. Carrillo-Vico A, Guerrero JM, Lardone PJ, et al., A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200. (Pubitemid 41558451)
50. Rodriguez MI, Escames G, Lopez LC, et al., Improved mitochondrial function and increased life span after chronic melatonin treatment in senescent prone mice. Exp Gerontol 2008; 43: 749-756.
51. Lee YD, Kim JY, Lee KH, et al., Melatonin attenuates lipopolysaccharide- induced acute lung inflammation in sleep-deprived mice. J Pineal Res 2009; 46: 53-57.
52. Mann DL,. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998. (Pubitemid 35416635)
53. Pinsky DJ, Cai B, Yang X, et al., The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995; 95: 677-685.
54. Tan DX, Manchester LC, Reiter RJ, et al., Significance of melatonin in antioxidative defense system: reactions and products. Biol Signal Recept 2000; 9: 137-159. (Pubitemid 30481268)
55. Tan DX, Manchester LC, Terron MP, et al., One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42. (Pubitemid 44924323)
56. Reiter RJ,. Melatonin: lowering the High Price of Free Radicals. News Physiol Sci 2000; 15: 246-250.
57. Hardeland R,. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cell Mol Life Sci 2008; 65: 2001-2018.